Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes

194Citations
Citations of this article
118Readers
Mendeley users who have this article in their library.
Get full text

Abstract

The main aim of pharmaceutical technology research is the design of successful formulations for effective therapy, taking into account several issues including therapeutic requirements and patient compliance. In this regard, several achievements have been reported with colloidal carriers, in particular with lipid nanoparticles, due to their unique physicochemical properties. For several years these carriers have been showing potential success for several administration routes, namely oral, dermal, parenteral, and, more recently, for pulmonary and brain targeting. The present chapter provides a review of the use of solid lipid nanoparticles (SLN) and nanostructured lipid carriers (NLC) to modify the release profile and the pharmacokinetic parameters of active pharmaceutical ingredients (APIs) incorporated in these lipid matrices, aiming to modify the API bioavailability, either upwards or downwards depending on the therapeutic requirement. Definitions of the morphological characteristics, surface properties, and polymorphic structures will also be given, emphasizing their influence on the incorporation parameters of the API, such as yield of production, loading capacity, and encapsulation efficiency. © 2009 Springer-Verlag Berlin Heidelberg.

Cite

CITATION STYLE

APA

Souto, E. B., & Müller, R. H. (2010). Lipid nanoparticles: Effect on bioavailability and pharmacokinetic changes. Handbook of Experimental Pharmacology. https://doi.org/10.1007/978-3-642-00477-3_4

Register to see more suggestions

Mendeley helps you to discover research relevant for your work.

Already have an account?

Save time finding and organizing research with Mendeley

Sign up for free